Investment

BioAesthetics Announces a $5M Series A to Commercialize NACgraft, a Regenerative Nipple Graft for Breast Cancer Survivors

BioAesthetics Corporation today announced that it has doubled its initial Series A funding goal of $2.5 million, closed on Dec. 30, 2020, at $5 million to commercialize its NACgraft biologic matrix— a regenerative nipple graft for breast cancer survivors. BioAesthetics’ Series A was co-led by FemHealth Ventures and personally by BioAesthetics’ Director Sandra Coufal, MD, of Sibling Capital Ventures. BioAesthetics’ inaugural product, the NACgraft — for patients…

Rhia Ventures Invests in OCON Healthcare’s Ballerine, the First 3D Spherical Copper Intrauterine Contraceptive

Rhia Ventures has invested in Israel-based OCON Healthcare to assist the US launch of Ballerine, the first and only 3D spherical copper IUB (Intrauterine Ball). Ballerine’s unique shape reduces irritation to the endometrium with fewer malpositions and perforations, which are significant drawbacks associated with current T-shaped IUDs. The financing will also help expand Phase II clinical trials for OCON’s SEAD product, which offers point-of-care…

Attn:Grace Adds 900K in Funding and Announces Strategic Collaboration with AARP Innovation Labs to Destigmatize Women’s Aging

Today Attn: Grace, a subscription-based, sustainable wellness brand for women as they age, announced the launch of a new, strategic collaboration with AARP Innovation Labs and an additional round of $900,000 in pre-seed funding. Tusk Venture Partners led the round, joined by existing investor, Precursor Ventures, and new investors Joyance Partners and Social Starts. This brings Attn: Grace’s total funding to $2 million…

Babyscripts Nabs $4M from Network of Health System investors

D.C. maternal health startup Babyscripts has raised millions of dollars in fresh funding from a group of health systems and organizations amid heightened demand fueled by a pandemic-era surge in telemedicine. The company, whose virtual obstetrics platform connects pregnant patients with their doctors, said Tuesday it has secured $4 million from what it’s calling its Strategic Partners Program. That network comprises existing…

Everlywell Raises $175 Million to Expand Consumer Lab Testing and Digital Health Offerings

Everlywell today announced an oversubscribed Series D financing of $175 million. New investors participating in the round include funds and accounts managed by BlackRock, The Chernin Group (TCG), Foresite Capital, Greenspring Associates, Lux Capital, Morningside Ventures, and Portfolia, as well as existing investors Goodwater Capital, Highland Capital Partners, and Next Coast Ventures. This investment brings the total capital raised by the company to…

Breast Cancer Technology Company Endomag Secures £15M in Series D Funding

Cambridge-based startup Endomag, has raised a £15M Series D led by Draper Esprit, which was supported by existing investors Sussex Place Ventures among others. This investment brings the company’s total funding to over £32 million. Endomag’s technologies use non-invasive magnetic sensing to locate and stage breast cancer and have helped over 130,000 women across the world receive more precise and less invasive…

Star Power: Dakota Johnson Joins Sexual Wellness Brand Maude as Investor and Co-Creative Director

From “50 Shades” to Maude: Dakota Johnson has recently announced her new role as investor and co-creative director of sexual wellness brand Maude. “Not only is maude a WOC-founded company, it is boldly and intelligently forward thinking in an industry where the conversation and narrative around intimacy products is antiquated. I believe that sexual wellness is a fundamental human right. Consensual sex…

Contraline Receives $1M Investment from the Male Contraceptive Initiative to further Developement of ADAM, an “IUD for Men”

Male Contraceptive Initiative, a 501(c)(3) non-profit, today announced that it has partnered with the medical device company Contraline to provide a $1 million Program Related Investment to support a first-in-human clinical trial for the company’s novel vas-occlusive contraceptive device, ADAM™. This is the first PRI from Male Contraceptive Initiative and is representative of the organization’s continued evolution. “We are very excited about…